News
The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger
Wednesday, March 05, 2025ACELYRIN INC and Alumis Inc reaffirmed their commitment to merge in an allstock transaction which will create a leading clinical stage biopharma company in immunemediated diseases Martin Babler President Chief Executive Officer and Chairman of Alumis...
Optime Care Partners with Eton Pharmaceuticals as a Specialty Pharmacy Provider for GALZIN®
Wednesday, March 05, 2025Optime Care a nationally recognized specialty pharmacy and an AscellaHealth Company today announces an expanded partnership with Eton Pharmaceuticals Eton an innovative pharmaceutical company focused on developing and commercializing treatments for r...
Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis
Tuesday, March 04, 2025Pliant Therapeutics Inc announced that following a prespecified data review and recommendation by the trials independent Data Safety Monitoring Board DSMB as well as a secondary review and recommendation by an outside expert panel Pliant has disconti...
Gensaic Announces Collaboration with Novo Nordisk to Unlock Next Generation Precision Therapies
Tuesday, March 04, 2025Gensaic Inc Gensaic a biotechnology company that combines AIpowered protein design with biological insights to discover ligands for tissueselective intracellular delivery today announced a license and discovery collaboration with Novo Nordisk a globa...
AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity
Monday, March 03, 2025AbbVie and Gubra AS a company specializing in preclinical contract research services and peptidebased drug discovery within metabolic and fibrotic diseases today announced a license agreement to develop GUB a potential bestinclass
US FDA Grants Priority Review to Sobi's Supplemental Biologics Licence Application for Gamifant
Friday, February 28, 2025Sobi has announced that the US Food and Drug Administration FDA has accepted the supplemental Biologics License Application sBLA for Gamifant emapalumablzsg The application seeks approval for use in adult and paediatric patients with haemophagocytic
Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Systemic Sclerosis Treatment
Friday, February 28, 2025Adicet Bio Inc a biotechnology company focused on developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer has received Fast Track Designation from the US Food and Drug Administration FDA for ADI as a potential treatment...
Pyxis Oncology Receives FDA Fast Track Designation for PYX-201 in Head and Neck Cancer Treatment
Thursday, February 27, 2025Pyxis Oncology Inca clinicalstage company developing advanced cancer therapies has been granted Fast Track Designation by the US Food and Drug Administration FDA for PYX This designation applies to the treatment of adults with recurrent
IPA and RIBOPRO Collaborate to Advance mRNA-Driven Antibody Discovery in Immunotherapy
Thursday, February 27, 2025ImmunoPrecise Antibodies Ltd a global company specialising in AIpowered antibody discovery and development has formed a strategic collaboration with RIBOPRO a technology provider focused on mRNA and lipid nanoparticle LNP technologies
Allogene Therapeutics Strengthens Partnership with Foresight Diagnostics to Support Development Efforts Beyond the US in Europe, the UK, Canada, and Australia
Wednesday, February 26, 2025Allogene Therapeutics Inc a clinicalstage biotechnology company focused on developing allogeneic CAR T AlloCAR T therapies for cancer and autoimmune diseases has broadened its partnership with Foresight Diagnostics Inc
